Tag Archive for: Phase II trials

After a brief market exit in November 2022, GSK appears to be giving its multiple myeloma treatment Blenrep a second chance, with company executives touting its “multi-blockbuster” potential in a virtual oncology-focused investor event on Monday.

The pipeline culling comes as Roche sustains a slight dip in sales. From January to September 2023, the pharma group made over $49 billion, compared with $52.48 billion during the same period in 2022.